Edition:
United Kingdom

argenx SE (ARGX.BR)

ARGX.BR on Brussels Stock Exchange

131.30EUR
17 Jul 2019
Change (% chg)

-- (--)
Prev Close
€131.30
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
106,802
52-wk High
€132.40
52-wk Low
€54.30

Latest Key Developments (Source: Significant Developments)

Argenx Plans To Launch A Phase 2 Trial In CIDP Before End Of 2019
Tuesday, 28 May 2019 

May 28 (Reuters) - ARGENX SE ::IS PLANNING TO LAUNCH A PHASE 2 PROOF-OF-CONCEPT TRIAL IN CIDP BEFORE END OF 2019.PHASE 2 PROOF-OF-CONCEPT TRIAL OF IV EFGARTIGIMOD IS ONGOING IN PV AND DATA ARE EXPECTED IN 2020.SECOND PHASE 3 PROGRAM OF EFGARTIGIMOD IS EXPECTED TO LAUNCH THIS YEAR IN ITP.  Full Article

Argenx Announces Pipeline Expansion And “Argenx 2021” Vision
Wednesday, 22 May 2019 

May 22 (Reuters) - ARGENX SE ::ARGENX ANNOUNCES PIPELINE EXPANSION AND “ARGENX 2021” VISION TO BUILD INTEGRATED IMMUNOLOGY COMPANY AT 2019 RESEARCH AND DEVELOPMENT DAY.EXPANDS PIPELINE WITH ARGX-117 AND ARGX-118; TWO NEW PIPELINE CANDIDATES FROM ITS INNOVATIVE ACCESS PROGRAM ADDRESSING FIRST-IN-CLASS TARGETS.A FIRST PHASE 2 REGISTRATION-DIRECTED TRIAL IN ACUTE MYELOID LEUKEMIA (AML) IS EXPECTED TO START IN SECOND HALF OF 2019.TODAY, ARGENX WILL ALSO BRING FORWARD ITS "ARGENX 2021" VISION.BY END OF 2021, ARGENX EXPECTS TO LAUNCH EFGARTIGIMOD IN U.S. IN ITS FIRST INDICATION GMG, IF APPROVED..ARGX-117 FIRST-IN-HUMAN CLINICAL STUDIES ARE EXPECTED TO START IN Q1 OF 2020.ITS PARTNER JANSSEN INTENDS TO INITIATE IN SECOND HALF OF 2019 ITS FIRST PHASE 2 AND REGISTRATION-DIRECTED CLINICAL TRIAL OF CUSATUZUMAB.PHASE 2 OF CUSATUZUMAB EXPECTED TO ENROLL UP TO 150 PATIENTS.PHASE 2 OF CUSATUZUMAB TWO-PART TRIAL.  Full Article

Argenx FY Operating Loss Widens To 81.8 Million Euros
Thursday, 28 Feb 2019 

Feb 28 (Reuters) - ARGENX SE ::FY REVENUE EUR 21.5 MILLION VERSUS EUR 36.4 MILLION YEAR AGO.FY TOTAL OPERATING INCOME EUR 29.2 MILLION VERSUS EUR 41.3 MILLION YEAR AGO.FY OPERATING LOSS EUR 81.8 MILLION VERSUS LOSS OF EUR 22.9 MILLION YEAR AGO.TO LAUNCH PHASE 3 CLINICAL TRIAL WITH EFGARTIGIMOD IN ITP IN SECOND HALF OF 2019.FY TOTAL COMPREHENSIVE LOSS OF THE PERIOD EUR 66.6 MILLION VERSUS LOSS OF EUR 28.1 MILLION YEAR AGO.TO LAUNCH PHASE 2 CLINICAL TRIAL WITH SUBCUTANEOUS FORMULATION OF EFGARTIGIMOD IN ITP IN FIRST HALF OF 2019.TO LAUNCH PHASE 1 CLINICAL TRIAL WITH SUBCUTANEOUS ENHANZE® FORMULATION OF EFGARTIGIMOD IN HEALTHY VOLUNTEERS IN 2019.CASH, CASH EQUIVALENTS AND CURRENT FINANCIAL ASSETS TOTALED €564.6 MILLION AS OF DECEMBER 31, 2018, COMPARED TO €359.8 MILLION ON DECEMBER 31, 2017.TO LAUNCH PHASE 2 CLINICAL TRIAL WITH EFGARTIGIMOD IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY BEFORE END OF 2019.TO CONTINUE ENROLLMENT OF EFGARTIGIMOD IN ONGOING PHASE 3 ADAPT AND ADAPT+ TRIALS IN GMG.  Full Article

Argenx And Halozyme Enter Global Collaboration And License Agreement For Enhanze Technology
Monday, 4 Feb 2019 

Feb 4 (Reuters) - ARGENX SE ::REG-ARGENX AND HALOZYME ENTER GLOBAL COLLABORATION AND LICENSE AGREEMENT FOR ENHANZE® TECHNOLOGY.AGREEMENT PROVIDES ARGENX EXCLUSIVE ACCESS TO ENHANZE® FOR ANY PRODUCT TARGETING HUMAN NEONATAL FC RECEPTOR FCRN, INCLUDING ARGENX'S LEAD ASSET EFGARTIGIMOD (ARGX-113) AND UP TO TWO ADDITIONAL TARGETS.HALOZYME WILL ALSO RECEIVE MID-SINGLE DIGIT ROYALTIES ON SALES OF COMMERCIALIZED PRODUCTS.POTENTIAL FUTURE PAYMENTS OF UP TO $160 MILLION PER SELECTED TARGET SUBJECT TO ACHIEVEMENT OF SPECIFIED DEVELOPMENT, REGULATORY AND SALES-BASED MILESTONES.ARGENX WILL PAY AN UPFRONT PAYMENT OF $30 MILLION TO HALOZYME.ARGENX WILL PAY $10 MILLION PER TARGET FOR FUTURE TARGET NOMINATIONS.  Full Article

Argenx Provides Detailed Data From Phase 2 Clinical Trial Of Efgartigimod
Monday, 3 Dec 2018 

Dec 3 (Reuters) - ARGENX SE ::REG-ARGENX PROVIDES DETAILED DATA FROM PHASE 2 CLINICAL TRIAL OF EFGARTIGIMOD IN IMMUNE THROMBOCYTOPENIA AND PHASE 1/2 CLINICAL TRIAL OF CUSATUZUMAB IN ACUTE MYELOID LEUKEMIA.NEW CUSATUZUMAB DATA IN AML RESULTED IN A 92% RESPONSE RATE WITH 10 OF 12 PATIENTS SHOWING A COMPLETE RESPONSE (CR/CRI).ITP PROGRAM EXPECTED TO ADVANCE TO PHASE 3 WITH IV EFGARTIGIMOD AND PHASE 2 WITH SUBCUTANEOUS FORMULATION.DETAILED PHASE 2 ITP DATA SHOW CLEAR CORRELATION BETWEEN IGG REDUCTION, PLATELET COUNT INCREASE AND REDUCTION OF BLEEDING EVENTS.  Full Article

Argenx Raises About $300.6 Mln In Gross Proceeds In U.S. Public Offering
Wednesday, 19 Sep 2018 

Sept 18 (Reuters) - argenx SE ::REG-ARGENX RAISES APPROXIMATELY $300.6 MILLION IN GROSS PROCEEDS IN A U.S. PUBLIC OFFERING.ARGENX SE -PRICING OF AN UNDERWRITTEN PUBLIC OFFERING IN UNITED STATES AND AN OFFERING IN EUROPE ONLY TO QUALIFIED INVESTORS.ARGENX SE -PRICING OFFERED WITH ANTICIPATED GROSS PROCEEDS TOTALLING ABOUT $300.6 MILLION FROM SALE OF 3,475,000 ADSS AT $86.50 PER ADS.ARGENX SE -EACH OF ADSS OFFERED REPRESENTS RIGHT TO RECEIVE ONE ORDINARY SHARE, NOMINAL VALUE OF EUR 0.10 PER SHARE.  Full Article

Argenx Announces Launch Of Proposed Public Offering In The U.S.
Monday, 17 Sep 2018 

Sept 17 (Reuters) - Argenx Se ::ARGENX ANNOUNCES LAUNCH OF PROPOSED PUBLIC OFFERING IN THE UNITED STATES.COMMENCED UNDERWRITTEN U.S. PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES AND AN OFFERING OF ADSS IN EUROPE ONLY TO QUALIFIED INVESTORS.ADS FOR APPROXIMATELY $300 MILLION.EACH OF ADSS OFFERED IN OFFERING REPRESENTS RIGHT TO RECEIVE ONE ORDINARY SHARE, NOMINAL VALUE OF EUR 0.10 PER SHARE.ALL OF THE ADSS IN THE PROPOSED OFFERING ARE TO BE SOLD BY ARGENX.  Full Article

Argenx Says Abbvie Exercises Exclusive Option To License Argx-115
Wednesday, 22 Aug 2018 

Aug 22 (Reuters) - ARGENX SE ::REG-ARGENX ANNOUNCES THAT ABBVIE HAS EXERCISED ITS EXCLUSIVE OPTION TO LICENSE ARGX-115, A NOVEL IMMUNO-ONCOLOGY ANTIBODY.EXERCISE BY ABBVIE OF ITS EXCLUSIVE LICENSE OPTION TO DEVELOP AND COMMERCIALIZE ARGX-115.ARGENX AND ABBVIE ENTERED INTO AN OPTION AND LICENSE AGREEMENT FOR ARGX-115 IN APRIL 2016.  Full Article

Argenx ‍Announces Expansion Of Its Pipeline
Thursday, 22 Mar 2018 

March 22 (Reuters) - ARGENX NV ::‍ANNOUNCES EXPANSION OF ITS PIPELINE WITH ADDITION OF COMPLEMENT-TARGETED ARGX-117 FOR TREATMENT OF SEVERE AUTOIMMUNE DISEASES​.  Full Article

Argenx Reports Fourth Quarter Business Update And Full Year 2017 Financial Results
Thursday, 1 Mar 2018 

March 1 (Reuters) - Argenx Nv ::ARGENX REPORTS FOURTH QUARTER BUSINESS UPDATE AND FULL YEAR 2017 FINANCIAL RESULTS.  Full Article